Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  CSL Limited    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

CSL : Commences Manufacturing Of University Of Oxford/Astrazeneca Vaccine Candidate In Melbourne

11/07/2020 | 08:37pm EST

Nov 7 (Reuters) - CSL Limited:

* CSL COMMENCES MANUFACTURING OF UNIVERSITY OF OXFORD/ASTRAZENECA VACCINE CANDIDATE IN MELBOURNE

* CSL - WILL COMMENCE MANUFACTURING OF OXFORD/ASTRAZENECA VACCINE AZD1222 COVID-19 VACCINE CANDIDATE AT ITS FACILITY IN BROADMEADOWS, ON MONDAY, NOV 9

* CSL - MANUFACTURING PROCESS OF OXFORD/ASTRAZENECA VACCINE CANDIDATE WILL START WITH THE THAW OF VIALS CONTAINING VACCINE CELLS

* CSL - HAS SEPARATE CONTRACTS WITH ASTRAZENECA, THE AUSTRALIAN GOVERNMENT TO MANUFACTURE ABOUT 30 MILLION DOSES OF THE AZD1222 VACCINE CANDIDATE

* CSL - FIRST DOSES PLANNED FOR RELEASE IN THE FIRST HALF OF 2021, PENDING THE OUTCOME OF CLINICAL TRIALS AND REGULATORY Source : https://bit.ly/2IfVttt Further company coverage:


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.12% 7748 Delayed Quote.4.62%
CSL LIMITED 0.09% 267.5 End-of-day quote.-5.54%
All news about CSL LIMITED
01/18Australia shares jump 1% on reports Queensland to lift lockdown curbs
RE
01/12Australia blocks Chinese buyout of builder over security concerns -media
RE
01/11Gold miners drag down Australian shares; NZ falls 2%
RE
01/08Australia shares notch best week in 2 months on broader global rally
RE
01/07MARKET CHATTER : CSL to Finish Production of First Batch of AstraZeneca COVID-19..
MT
01/06Australian shares end 1% lower as U.S. runoff results trickle in
RE
01/05Australia shares open lower as domestic virus concerns weigh
RE
2020Australia shares dip on Sydney restrictions, NZ inches down
RE
2020Australian shares track Wall Street declines; NZ flat
RE
2020Australia shares climb as U.S. aid bill passage boosts sentiment, NZ at recor..
RE
More news
Financials (USD)
Sales 2021 10 127 M - -
Net income 2021 2 246 M - -
Net Debt 2021 4 747 M - -
P/E ratio 2021 41,7x
Yield 2021 1,06%
Capitalization 93 526 M 93 519 M -
EV / Sales 2021 9,70x
EV / Sales 2022 9,00x
Nbr of Employees 27 000
Free-Float 100,0%
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | CSL | AU000000CSL8 | MarketScreener
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 229,27 $
Last Close Price 205,56 $
Spread / Highest target 22,1%
Spread / Average Target 11,5%
Spread / Lowest Target -5,07%
EPS Revisions
Managers and Directors
NameTitle
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
Brian Anthony McNamee Chairman
Paul McKenzie Chief Operating Officer
Joy Carolyn Linton Chief Financial Officer
Andrew Cuthbertson Chief Scientific Officer & Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
CSL LIMITED-5.54%93 519
SAMSUNG BIOLOGICS CO.,LTD.-4.60%47 194
BIOGEN INC.12.65%42 447
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.-4.50%34 810
ALEXION PHARMACEUTICALS, INC.0.29%34 293
UCB1.89%19 643